Kurse werden geladen...
Prognose
| Kaufen | 0 |
| Halten | 1 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES , April 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.» Mehr auf prnewswire.com
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES , March 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.» Mehr auf prnewswire.com
Shareholder Rights Advocates at Levi & Korsinsky Investigate Allarity Therapeutics, Inc. (ALLR) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity Therapeutics, Inc.") (NASDAQ:ALLR) concerning possible violations of federal securities laws. On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC.» Mehr auf accessnewswire.com
Unternehmenszahlen
| (EUR) | Dez. 2024 | |
|---|---|---|
| Umsatz | 0,00 | 100,00% |
| Bruttoeinkommen | 0,00 | 100,00% |
| Nettoeinkommen | −7,16 Mio | 359,80% |
| EBITDA | −7,09 Mio | 459,79% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 14,06 Mio€ |
Anzahl Aktien | 17,01 Mio |
52 Wochen-Hoch/Tief | 91,27€ - 0,54€ |
| Dividenden | Nein |
Beta | -0,07 |
KGV (PE Ratio) | −0,03 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,05 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
| Name | Allarity Therapeutics Aktie |
| CEO | Thomas H. Jensen |
| Mitarbeiter | 6 |
Assets entdecken
Shareholder von Allarity Therapeutics Aktie investieren auch in folgende Assets
